FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914462041> ?p ?o ?g. }

• W2914462041 endingPage "1876.e9" @default.
• W2914462041 startingPage "1862" @default.
• W2914462041 abstract "Background & AimsHepatocellular carcinoma (HCC) is often associated with hepatitis B virus (HBV) infection. Cells of most HBV-related HCCs contain HBV-DNA fragments that do not encode entire HBV antigens. We investigated whether these integrated HBV-DNA fragments encode epitopes that are recognized by T cells and whether their presence in HCCs can be used to select HBV-specific T-cell receptors (TCRs) for immunotherapy.MethodsHCC cells negative for HBV antigens, based on immunohistochemistry, were analyzed for the presence of HBV messenger RNAs (mRNAs) by real-time polymerase chain reaction, sequencing, and Nanostring approaches. We tested the ability of HBV mRNA-positive HCC cells to generate epitopes that are recognized by T cells using HBV-specific T cells and TCR-like antibodies. We then analyzed HBV gene expression profiles of primary HCCs and metastases from 2 patients with HCC recurrence after liver transplantation. Using the HBV-transcript profiles, we selected, from a library of TCRs previously characterized from patients with self-limited HBV infection, the TCR specific for the HBV epitope encoded by the detected HBV mRNA. Autologous T cells were engineered to express the selected TCRs, through electroporation of mRNA into cells, and these TCR T cells were adoptively transferred to the patients in increasing numbers (1 × 104–10 × 106 TCR+ T cells/kg) weekly for 112 days or 1 year. We monitored patients’ liver function, serum levels of cytokines, and standard blood parameters. Antitumor efficacy was assessed based on serum levels of alpha fetoprotein and computed tomography of metastases.ResultsHCC cells that did not express whole HBV antigens contained short HBV mRNAs, which encode epitopes that are recognized by and activate HBV-specific T cells. Autologous T cells engineered to express TCRs specific for epitopes expressed from HBV-DNA in patients’ metastases were given to 2 patients without notable adverse events. The cells did not affect liver function over a 1-year period. In 1 patient, 5 of 6 pulmonary metastases decreased in volume during the 1-year period of T-cell administration.ConclusionsHCC cells contain short segments of integrated HBV-DNA that encodes epitopes that are recognized by and activate T cells. HBV transcriptomes of these cells could be used to engineer T cells for personalized immunotherapy. This approach might be used to treat a wider population of patients with HBV-associated HCC. Hepatocellular carcinoma (HCC) is often associated with hepatitis B virus (HBV) infection. Cells of most HBV-related HCCs contain HBV-DNA fragments that do not encode entire HBV antigens. We investigated whether these integrated HBV-DNA fragments encode epitopes that are recognized by T cells and whether their presence in HCCs can be used to select HBV-specific T-cell receptors (TCRs) for immunotherapy. HCC cells negative for HBV antigens, based on immunohistochemistry, were analyzed for the presence of HBV messenger RNAs (mRNAs) by real-time polymerase chain reaction, sequencing, and Nanostring approaches. We tested the ability of HBV mRNA-positive HCC cells to generate epitopes that are recognized by T cells using HBV-specific T cells and TCR-like antibodies. We then analyzed HBV gene expression profiles of primary HCCs and metastases from 2 patients with HCC recurrence after liver transplantation. Using the HBV-transcript profiles, we selected, from a library of TCRs previously characterized from patients with self-limited HBV infection, the TCR specific for the HBV epitope encoded by the detected HBV mRNA. Autologous T cells were engineered to express the selected TCRs, through electroporation of mRNA into cells, and these TCR T cells were adoptively transferred to the patients in increasing numbers (1 × 104–10 × 106 TCR+ T cells/kg) weekly for 112 days or 1 year. We monitored patients’ liver function, serum levels of cytokines, and standard blood parameters. Antitumor efficacy was assessed based on serum levels of alpha fetoprotein and computed tomography of metastases. HCC cells that did not express whole HBV antigens contained short HBV mRNAs, which encode epitopes that are recognized by and activate HBV-specific T cells. Autologous T cells engineered to express TCRs specific for epitopes expressed from HBV-DNA in patients’ metastases were given to 2 patients without notable adverse events. The cells did not affect liver function over a 1-year period. In 1 patient, 5 of 6 pulmonary metastases decreased in volume during the 1-year period of T-cell administration. HCC cells contain short segments of integrated HBV-DNA that encodes epitopes that are recognized by and activate T cells. HBV transcriptomes of these cells could be used to engineer T cells for personalized immunotherapy. This approach might be used to treat a wider population of patients with HBV-associated HCC." @default.
• W2914462041 created "2019-02-21" @default.
• W2914462041 creator A5000634003 @default.
• W2914462041 creator A5008236591 @default.
• W2914462041 creator A5008909013 @default.
• W2914462041 creator A5011853295 @default.
• W2914462041 creator A5012099171 @default.
• W2914462041 creator A5019504988 @default.
• W2914462041 creator A5019899138 @default.
• W2914462041 creator A5025064842 @default.
• W2914462041 creator A5026984704 @default.
• W2914462041 creator A5027445044 @default.
• W2914462041 creator A5036947659 @default.
• W2914462041 creator A5039286311 @default.
• W2914462041 creator A5044822674 @default.
• W2914462041 creator A5059405939 @default.
• W2914462041 creator A5060464343 @default.
• W2914462041 creator A5061899703 @default.
• W2914462041 creator A5072332593 @default.
• W2914462041 creator A5073419696 @default.
• W2914462041 creator A5074307736 @default.
• W2914462041 creator A5082864878 @default.
• W2914462041 creator A5083513301 @default.
• W2914462041 date "2019-05-01" @default.
• W2914462041 modified "2023-10-15" @default.
• W2914462041 title "Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy" @default.
• W2914462041 cites W1556179571 @default.
• W2914462041 cites W1593832483 @default.
• W2914462041 cites W1966914270 @default.
• W2914462041 cites W1971837077 @default.
• W2914462041 cites W1975913349 @default.
• W2914462041 cites W1985749562 @default.
• W2914462041 cites W1994993231 @default.
• W2914462041 cites W1995462034 @default.
• W2914462041 cites W2000705595 @default.
• W2914462041 cites W2012392646 @default.
• W2914462041 cites W2012670008 @default.
• W2914462041 cites W2027828064 @default.
• W2914462041 cites W2038840174 @default.
• W2914462041 cites W2053900193 @default.
• W2914462041 cites W2068175847 @default.
• W2914462041 cites W2073213047 @default.
• W2914462041 cites W2076038974 @default.
• W2914462041 cites W2076125315 @default.
• W2914462041 cites W2084590325 @default.
• W2914462041 cites W2099570622 @default.
• W2914462041 cites W2105327344 @default.
• W2914462041 cites W2105853552 @default.
• W2914462041 cites W2120164503 @default.
• W2914462041 cites W2152798078 @default.
• W2914462041 cites W2157715173 @default.
• W2914462041 cites W2161841913 @default.
• W2914462041 cites W2177689130 @default.
• W2914462041 cites W2252614391 @default.
• W2914462041 cites W2283978743 @default.
• W2914462041 cites W2286667211 @default.
• W2914462041 cites W2560499218 @default.
• W2914462041 cites W2562858382 @default.
• W2914462041 cites W2592906764 @default.
• W2914462041 cites W2606367731 @default.
• W2914462041 cites W2737143554 @default.
• W2914462041 cites W2757654367 @default.
• W2914462041 cites W2761031851 @default.
• W2914462041 cites W2783333335 @default.
• W2914462041 cites W2786747248 @default.
• W2914462041 cites W2792595263 @default.
• W2914462041 cites W2804015468 @default.
• W2914462041 cites W2804159084 @default.
• W2914462041 doi "https://doi.org/10.1053/j.gastro.2019.01.251" @default.
• W2914462041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30711630" @default.
• W2914462041 hasPublicationYear "2019" @default.
• W2914462041 type Work @default.
• W2914462041 sameAs 2914462041 @default.
• W2914462041 citedByCount "84" @default.
• W2914462041 countsByYear W29144620412019 @default.
• W2914462041 countsByYear W29144620412020 @default.
• W2914462041 countsByYear W29144620412021 @default.
• W2914462041 countsByYear W29144620412022 @default.
• W2914462041 countsByYear W29144620412023 @default.
• W2914462041 crossrefType "journal-article" @default.
• W2914462041 hasAuthorship W2914462041A5000634003 @default.
• W2914462041 hasAuthorship W2914462041A5008236591 @default.
• W2914462041 hasAuthorship W2914462041A5008909013 @default.
• W2914462041 hasAuthorship W2914462041A5011853295 @default.
• W2914462041 hasAuthorship W2914462041A5012099171 @default.
• W2914462041 hasAuthorship W2914462041A5019504988 @default.
• W2914462041 hasAuthorship W2914462041A5019899138 @default.
• W2914462041 hasAuthorship W2914462041A5025064842 @default.
• W2914462041 hasAuthorship W2914462041A5026984704 @default.
• W2914462041 hasAuthorship W2914462041A5027445044 @default.
• W2914462041 hasAuthorship W2914462041A5036947659 @default.
• W2914462041 hasAuthorship W2914462041A5039286311 @default.
• W2914462041 hasAuthorship W2914462041A5044822674 @default.
• W2914462041 hasAuthorship W2914462041A5059405939 @default.
• W2914462041 hasAuthorship W2914462041A5060464343 @default.
• W2914462041 hasAuthorship W2914462041A5061899703 @default.
• W2914462041 hasAuthorship W2914462041A5072332593 @default.
• W2914462041 hasAuthorship W2914462041A5073419696 @default.

• next